3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
Exercise
4
Cholecalciferol
4
Nutrition Assessment
3
Gonadotropin-Releasing Hormone
3
Blood Pressure
3
Atorvastatin
3
palbociclib
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
acalabrutinib
2
Vitamin E
2
Social Determinants of Health
2
Rosuvastatin Calcium
2
Metformin
2
Geritol
2
Fish Oils
2
Fatty Acids, Omega-3
2
Ethanol
2
Electrocardiography
2
Educational Status
2
Echocardiography
2
Diet, Mediterranean
2
Blood Specimen Collection
2
Aspirin
2
Antineoplastic Agents
2
Absorptiometry, Photon
2
zanubrutinib
1
xinmailong
1
ribociclib
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cardiovascular Diseases
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled